Skip to product information
1 of 4

Human BCMA/TNFRSF17 OneStep ELISA Kit

Human BCMA/TNFRSF17 OneStep ELISA Kit

Catalog Number: S0C3269 Reactivity: Hu Conjugation: Brand: Starter
Price:
Regular price $500 USD
Regular price Sale price $500 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Antigen BCMA/TNFRSF17
Immunogen Recombinant Protein
Antibody Type Recombinant mAb
Reactivity Hu
Purification Protein A
Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8°C as supplied.

Kit


Sample type Serum; EDTA Plasma, Heparin Plasma, Citrate Plasma; Cell Culture Supernatant
Assay type Sandwich (quantitative)
Range 0.2 ng/mL – 10 ng/mL
Assay time 60 minutes
Species reactivity Hu

Background

Human BCMA (B-cell maturation antigen), also known as TNFRSF17 or CD269, is a type III transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Encoded by the TNFRSF17 gene located on human chromosome 16, the protein consists of an extracellular N-terminal cysteine-rich domain, a transmembrane region, and a cytoplasmic C-terminal tail. Its expression is highly restricted, being predominantly found on mature B lymphocytes, particularly long-lived plasma cells, while absent from T cells and monocytes. Functionally, BCMA serves as the receptor for two key ligands, BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Upon ligand binding, BCMA activates multiple downstream signaling cascades, including the NF-κB and JNK pathways, through the recruitment of TRAF family members. These signals are critical for promoting B-cell survival, proliferation, and differentiation, thereby playing an essential role in humoral immunity. In pathological settings, BCMA has garnered significant clinical attention due to its overexpression on malignant plasma cells in multiple myeloma, where it provides crucial survival signals that protect tumor cells from apoptosis. This restricted expression profile makes BCMA an exceptionally attractive therapeutic target, particularly for chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable efficacy in treating relapsed or refractory multiple myeloma. Additionally, elevated levels of soluble BCMA in serum have emerged as a valuable biomarker for monitoring disease progression and assessing treatment response in myeloma patients, further underscoring the clinical relevance of this protein.

Picture

ELISA

Standard Curve
Example of Human BCMA/TNFRSF17 standard curve in Assay Diluent A1. Plotted are the background-subtracted data.
This standard curve is provided for demonstration only.

Dilution Linearity
The concentrations of Human BCMA/TNFRSF17 were measured and interpolated from the target standard curves and corrected for sample dilution.
The leftmost bar in the graph shows biological samples diluted in Assay Diluent to 25% concentration. "undiluted" was defined as 25% biological sample. The subsequent bars represent two-fold serial dilutions of this reference. The mean target concentration was determined to be 9.81 ng/mL in Human donor serum QXC468.

Dilution Linearity
The concentrations of Human BCMA/TNFRSF17 were measured and interpolated from the target standard curves and corrected for sample dilution.
The leftmost bar in the graph shows biological samples diluted in Assay Diluent to 25% concentration. "undiluted" was defined as 25% biological sample. The subsequent bars represent two-fold serial dilutions of this reference. The mean target concentration was determined to be 14.22 ng/mL in Human donor serum QXC467.

Protocol Diagram